Switch theme
Sign up to access all valuation multiples
Cochlear is the leading cochlear implant device manufacturer with around 60% global market share. Developed markets contribute 80% of group revenue where cochlear implants are the standard of care for children with severe to profound hearing loss. The company also actively targets the growing cohort of seniors in developed markets. Tender-oriented emerging markets contribute the remaining 20% of group revenue. Main products include cochlear implants, bone-anchored hearing aids, and associated sound processors. In fiscal 2020, 49% of revenue came from the Americas, 35% from Europe, the Middle East, and Africa, and 16% from the Asia-Pacific segment.
1983
5.3K+
LTM Revenue $1.5B
LTM EBITDA $401M
$12.7B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Cochlear has a last 12-month revenue (LTM) of $1.5B and a last 12-month EBITDA of $401M.
In the most recent fiscal year, Cochlear achieved revenue of $1.5B and an EBITDA of $378M.
Cochlear expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Cochlear valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $1.5B | XXX | $1.5B | XXX | XXX | XXX |
| Gross Profit | $1.1B | XXX | $1.1B | XXX | XXX | XXX |
| Gross Margin | 74% | XXX | 75% | XXX | XXX | XXX |
| EBITDA | $401M | XXX | $378M | XXX | XXX | XXX |
| EBITDA Margin | 26% | XXX | 26% | XXX | XXX | XXX |
| EBIT | $345M | XXX | $270M | XXX | XXX | XXX |
| EBIT Margin | 22% | XXX | 19% | XXX | XXX | XXX |
| Net Profit | $259M | XXX | $233M | XXX | XXX | XXX |
| Net Margin | 17% | XXX | 16% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of July 2, 2025, Cochlear's stock price is AUD 300 (or $196).
Cochlear has current market cap of AUD 19.6B (or $12.8B), and EV of AUD 19.5B (or $12.7B).
See Cochlear trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $12.7B | $12.8B | XXX | XXX | XXX | XXX | $3.96 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of July 2, 2025, Cochlear has market cap of $12.8B and EV of $12.7B.
Cochlear's trades at 8.5x EV/Revenue multiple, and 32.7x EV/EBITDA.
Equity research analysts estimate Cochlear's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Cochlear has a P/E ratio of 49.5x.
See valuation multiples for Cochlear and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $12.8B | XXX | $12.8B | XXX | XXX | XXX |
| EV (current) | $12.7B | XXX | $12.7B | XXX | XXX | XXX |
| EV/Revenue | 8.2x | XXX | 8.5x | XXX | XXX | XXX |
| EV/EBITDA | 31.8x | XXX | 32.7x | XXX | XXX | XXX |
| EV/EBIT | 36.9x | XXX | 41.4x | XXX | XXX | XXX |
| EV/Gross Profit | 11.1x | XXX | n/a | XXX | XXX | XXX |
| P/E | 49.5x | XXX | 52.1x | XXX | XXX | XXX |
| EV/FCF | 53.3x | XXX | 58.7x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialCochlear's last 12 month revenue growth is 10%
Cochlear's revenue per employee in the last FY averaged $0.3M, while opex per employee averaged $0.2M for the same period.
Cochlear's rule of 40 is 36% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Cochlear's rule of X is 52% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Cochlear and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 10% | XXX | 9% | XXX | XXX | XXX |
| EBITDA Margin | 26% | XXX | 26% | XXX | XXX | XXX |
| EBITDA Growth | 14% | XXX | 11% | XXX | XXX | XXX |
| Rule of 40 | 36% | XXX | 36% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 52% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.3M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.2M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 31% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 12% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 56% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Philips | XXX | XXX | XXX | XXX | XXX | XXX |
| Perspective Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| SmartVest | XXX | XXX | XXX | XXX | XXX | XXX |
| InfuSystem | XXX | XXX | XXX | XXX | XXX | XXX |
| Myomo | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Cochlear acquired XXX companies to date.
Last acquisition by Cochlear was XXXXXXXX, XXXXX XXXXX XXXXXX . Cochlear acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Cochlear founded? | Cochlear was founded in 1983. |
| Where is Cochlear headquartered? | Cochlear is headquartered in Australia. |
| How many employees does Cochlear have? | As of today, Cochlear has 5.3K+ employees. |
| Who is the CEO of Cochlear? | Cochlear's CEO is Mr. Dig Howitt. |
| Is Cochlear publicy listed? | Yes, Cochlear is a public company listed on ASX. |
| What is the stock symbol of Cochlear? | Cochlear trades under COH ticker. |
| When did Cochlear go public? | Cochlear went public in 1995. |
| Who are competitors of Cochlear? | Similar companies to Cochlear include e.g. Philips, Perspective Therapeutics, SmartVest, InfuSystem. |
| What is the current market cap of Cochlear? | Cochlear's current market cap is $12.8B |
| What is the current revenue of Cochlear? | Cochlear's last 12 months revenue is $1.5B. |
| What is the current revenue growth of Cochlear? | Cochlear revenue growth (NTM/LTM) is 10%. |
| What is the current EV/Revenue multiple of Cochlear? | Current revenue multiple of Cochlear is 8.2x. |
| Is Cochlear profitable? | Yes, Cochlear is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Cochlear? | Cochlear's last 12 months EBITDA is $401M. |
| What is Cochlear's EBITDA margin? | Cochlear's last 12 months EBITDA margin is 26%. |
| What is the current EV/EBITDA multiple of Cochlear? | Current EBITDA multiple of Cochlear is 31.8x. |
| What is the current FCF of Cochlear? | Cochlear's last 12 months FCF is $239M. |
| What is Cochlear's FCF margin? | Cochlear's last 12 months FCF margin is 15%. |
| What is the current EV/FCF multiple of Cochlear? | Current FCF multiple of Cochlear is 53.3x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
